Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: J Hepatol. 2021 Aug 4;75(6):1335–1345. doi: 10.1016/j.jhep.2021.07.030

Fig. 4. Inhibition of HBV DNA, HBeAg and HBsAg by pegIFN-α2a in infected humanized chimeric mice.

Fig. 4.

HBVcc-infected humanized chimeric mice were treated with pegIFN-α2a (30 μg/kg) at week 10 post-infection and continued for 4 weeks. Mice serum was harvested weekly at indicated time points during the treatment period and continued for 6 weeks after treatment cessation. HBV DNA and hAlb in mice serum were analyzed using real time PCR and ELISA kit accordingly. (A) The changes of HBV DNA, HBeAg and HBsAg levels from the pre-treatment levels (week 10 of infection) were calculated and shown. The data of each mouse are denoted by a different color of symbols & lines. (B) the cumulative changes of HBV DNA during 4 weeks of pegIFN-α2a treatment were calculated as area under curve (AUC) from week 1–4 of treatment. The data are shown as means ± SEM of triplicates.